Kangrong Oriental

Kangrong Oriental is a Beijing-based biotechnology company specializing in the development of next-generation Natural Killer (NK) cell therapies for cancer treatment. The company's core technology, the K-NK platform, enables the large-scale expansion and activation of high-purity NK cells with enhanced anti-tumor activity. Their lead candidate, K-NK001, is being evaluated in clinical trials for various solid tumors, including liver and lung cancers, as well as hematological malignancies. Kangrong Oriental focuses on both autologous and allogeneic off-the-shelf cell therapy products to improve patient access and therapeutic outcomes. The company is supported by prominent venture capital firms and maintains a strong R&D presence in China's growing biopharmaceutical sector.